Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients
Our study suggests that <i>SLC5A2</i> variation is associated with clinical outcomes in SGLT2i-naïve and treated HF patients, warranting further investigation of <i>SLC5A2</i> and SGLT2i interactions.
Authors
- Neven Sarhan (ORCID: https://orcid.org/0000-0002-4067-5518)
- Rania M. Sarhan (ORCID: https://orcid.org/0000-0002-0781-6454)
- Abdullah Salah Alanazi (ORCID: https://orcid.org/0000-0002-8120-4018)
- Brian E. Gawronski (ORCID: https://orcid.org/0009-0000-9513-4244)
- Heba F. Salem (ORCID: https://orcid.org/0000-0002-4711-8511)
- Julio D. Duarte (ORCID: https://orcid.org/0000-0001-9766-4038)
- Christelle Lteif (ORCID: https://orcid.org/0000-0002-0468-8936)
- Leanne Dumeny (ORCID: https://orcid.org/0000-0003-3184-1235)
- Bassem Zarif (ORCID: https://orcid.org/0000-0002-0717-4084)
- Ayman Moharram (ORCID: https://orcid.org/0000-0003-1479-5476)
- Khaled Elenizi (ORCID: https://orcid.org/0000-0003-0316-1523)
- Ahmed Essam Abou Warda (ORCID: https://orcid.org/0000-0003-4434-6217)
- Tariq Ghazi Alsahli (ORCID: https://orcid.org/0000-0002-3001-867X)
- Mohamed Nabil Salem
- Rylie M. Flohr
Institutions
- Beni-Suef University (EG)
- Prince Sattam Bin Abdulaziz University (SA)
- Cairo University (EG)
- Jouf University (SA)
- PharmacoGenetics (China) (CN)
- National Heart Institute (EG)
- October 6 University (EG)
- Misr International University (EG)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fphar.2025.1539870
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88